- Home
- OPHC vs IPSC Comparison
OPHC vs IPSC Comparison
Compare OPHC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- IPSC
- Stock Information
- Founded
- OPHC 2000
- IPSC 2019
- Country
- OPHC United States
- IPSC United States
- Employees
- OPHC N/A
- IPSC N/A
- Industry
- OPHC Major Banks
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- OPHC Finance
- IPSC Health Care
- Exchange
- OPHC Nasdaq
- IPSC Nasdaq
- Market Cap
- OPHC 51.8M
- IPSC 47.4M
- IPO Year
- OPHC N/A
- IPSC 2021
- Fundamental
- Price
- OPHC $4.58
- IPSC $0.64
- Analyst Decision
- OPHC
- IPSC Strong Buy
- Analyst Count
- OPHC 0
- IPSC 5
- Target Price
- OPHC N/A
- IPSC $3.33
- AVG Volume (30 Days)
- OPHC 10.5K
- IPSC 857.5K
- Earning Date
- OPHC 08-05-2025
- IPSC 08-07-2025
- Dividend Yield
- OPHC N/A
- IPSC N/A
- EPS Growth
- OPHC 30.24
- IPSC N/A
- EPS
- OPHC 1.33
- IPSC N/A
- Revenue
- OPHC $39,980,000.00
- IPSC $114,898,000.00
- Revenue This Year
- OPHC N/A
- IPSC $1,590.09
- Revenue Next Year
- OPHC N/A
- IPSC N/A
- P/E Ratio
- OPHC $3.46
- IPSC N/A
- Revenue Growth
- OPHC 53.28
- IPSC 8286.72
- 52 Week Low
- OPHC $3.53
- IPSC $0.34
- 52 Week High
- OPHC $5.90
- IPSC $2.51
- Technical
- Relative Strength Index (RSI)
- OPHC 55.23
- IPSC 59.34
- Support Level
- OPHC $4.53
- IPSC $0.61
- Resistance Level
- OPHC $4.70
- IPSC $0.68
- Average True Range (ATR)
- OPHC 0.06
- IPSC 0.04
- MACD
- OPHC 0.00
- IPSC 0.01
- Stochastic Oscillator
- OPHC 42.86
- IPSC 62.84
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.